In addition, the second-generation EGFR inhibitor afatinib showed no effective outcomes in clinical trials for the treatment of primary or recurrent GBM [15]; these trials confirmed that afatinib barely penetrated the blood-brain barrier. This evidence concerns the gene EGFR and glioblastoma.